If you want to understand how different the human and animal medicine and vaccine industries have historically been, you don't need to look much further than weight loss drugs.
When Pfizer spun off its animal health business in 2013 creating Zoetis, about 65% of the company's business was livestock-related.
That has flipped now, with 64% of the company's revenue coming from products for companion animals like cats and dogs.
Peck credits the Pfizer spinoff for allowing Zoetis to better balance what the company wanted to do in animal health versus the human health side.
A similar product was approved for cats, marking the first time that monoclonal antibody treatments, which have become increasingly popular for treating human illnesses, have been used to treat pet osteoarthritis pain.
Persons:
Kristin Peck, Eli Lilly, Peck, Zoetis, We've, it's, We'll
Organizations:
CNBC, Novo Nordisk, Pfizer, AstraZeneca, FDA